Get it on Google Play

#140 – Beta-lactamase inhibitors: “Scientifically elegant, just complex"

#140 – Beta-lactamase inhibitors: “Scientifically elegant, just complex"

Author: Society of Infectious Diseases Pharmacists August 21, 2026 Duration: 1:16:18
Breakpoints
HealthEducationScience

Gram-negative resistance is beautifully intricate, scientifically elegant, and very complex. Nothing is more exciting than the recently approved and bursting pipeline of beta-lactamase inhibitors. Listen to Drs. Sam Aitken and Christophe Le Terrier, along with host Dr. Erin McCreary, describe the nuanced enzymology and other antibacterial properties of beta-lactamase inhibitors. This episode also discusses the concepts of stand-alone inhibitors, resistance development, and more. If you want to learn more about sulbactam, clavulanic acid, tazobactam, avibactam, relebactam, vaborbactam, durlobactam, enmetazobactam, zidebactam, nacubactam, ledaborbactam, taniborbactam, and xeruborbactam – this episode is for you!

Funding for this podcast was provided by Shionogi Inc.

References:

1.      Le Terrier C, Nordmann P, Buchs C, et al. Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern. J Antimicrob Chemother. 2023;78(9):2382-2384. doi:10.1093/jac/dkad210

2.      Le Terrier C, Nordmann P, Buchs C, Poirel L. Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum β-lactamases. Antimicrob Agents Chemother. 2024;68(4):e0154823. doi:10.1128/AAC.01548-23

3.      Le Terrier C, Freire S, Viguier C, Findlay J, Nordmann P, Poirel L. Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2024;68(6):e0157023. doi:10.1128/AAC.01570-23

4.      Le Terrier C, Mlynarcik P, Sadek M, Nordmann P, Poirel L. Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases. Antimicrob Agents Chemother. 2024;68(11):e0077524. doi:10.1128/AAC.00775-24

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About

Instagram: @SIDPharm ( https://www.instagram.com/sidpharm/) or @breakpointspodcast_sidp (https://www.instagram.com/breakpointspodcast_sidp/) https://www.instagram.com/breakpointspodcast_sidp/?hl=en

Facebook: https://www.facebook.com/sidprx

LinkedIn:  https://www.linkedin.com/company/sidp/

SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/https://sidp.pinecast.co/


Hosted by the Society of Infectious Diseases Pharmacists, Breakpoints is a podcast dedicated to the intricate and ever-evolving world of antimicrobial therapy. Each episode delves into the practical challenges and scientific nuances faced by pharmacists on the front lines of patient care, from interpreting susceptibility data and optimizing dosing strategies to navigating the complexities of antimicrobial stewardship. The conversations in this podcast bridge the gap between groundbreaking infectious diseases research and its direct application in clinical settings, offering insights that are both academically rigorous and immediately useful. You’ll hear expert discussions on new resistance patterns, evolving treatment guidelines, and the real-world implementation of life-saving protocols. Designed for healthcare professionals committed to precision medicine, Breakpoints provides a deeper understanding of how to effectively manage infections and improve patient outcomes. Tune in for thoughtful analysis and forward-thinking dialogue that defines the critical role of specialized pharmacists in public health.
Author: Language: en-us Episodes: 50

Official website RSS
instagramlinkedin
Breakpoints
Podcast Episodes
#141 – Prostatitis: Hard to Reach, Harder to Treat [not-audio_url] [/not-audio_url]

Duration: 58:30
Dr. Prathit Kulkarni, lead author of a recent state-of-the-art review on acute and chronic bacterial prostatitis, joins host Dr. Erin McCreary to discuss this complex disease state. They walk through diagnosis, epidemiol…
#139 – The ART of HIV Care: Evidence, Pearls and Practice [not-audio_url] [/not-audio_url]

Duration: 1:09:52
Join Dr. Whitney Buckel and leading HIV experts Dr. William Short and Dr. Ryan Tomlin for an engaging discussion on the current and future state of HIV care. As treatment and prevention options continue to evolve, clinic…
#135 – Stewie Struggles: Small Hospital Edition [not-audio_url] [/not-audio_url]

Duration: 1:02:43
Small hospitals bring unique stewardship challenges, but also unique opportunities. Dr. Tina Khadem and Dr. Ashley Cubillos join host Dr. Whitney Buckel to discuss the realities of antimicrobial stewardship in small and…
#134 – ESCMID Global Trials: PETER PEN and ASTARTE [not-audio_url] [/not-audio_url]

Duration: 1:03:15
Professor Mical Paul and Professor Jesús Rodríguez-Baño join Professor Josh Davis and Dr Erin McCreary for a special Breakpoints and Communicable podcast collaboration. This episode discusses the ‘Trials Run’ session at…

12345»